EMERGEX VACCINES HOLDING LIMITED Revenue and Competitors

Emergex, a UK-based biotechnology company headquartered in Abingdon, UK, is pioneering the development of set-point vaccines to address some of the world's most immediate health threats such as Dengue fever, Zika, Ebola, pandemic Flu and serious intra-cellular bacterial Infections. These set-point vaccines are population based and modify the initial immune status of recipients in a way that 'primes' their immune systems to recognise subsequent infectious agents much like a natural infection would do, preventing an acute or severe manifestation of the disease. Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines, including using synthetic peptide codes determined on actual infected cells and using a proprietary gold nanoparticle carrier system for programming. The Company has a growing pipeline of vaccine candidates. The most advanced development programme is a vaccine for Dengue Fever, which may also be disease modifying for other Flaviviruses such as the Zika and Yellow Fever viruses. Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus (including viruses such as Ebola and Marburg) and discovery programmes for Yellow Fever Booster vaccine and a Chikungunya vaccine.